Eli Lilly's Retatrutide Shows Strong Phase 3 Results in Obesity Trial
Eli Lilly reported positive results from the Phase 3 trial of its experimental obesity drug retatrutide. Patients receiving the highest dose lost an average of 28.3% body weight over 80 weeks, with more than 45% losing at least 30%. The data supports potential regulatory approval and positions retatrutide as a next-generation treatment in the growing obesity market.
Tickers: $LLY
Topics: Eli Lilly obesity drug Phase 3 trial results retatrutide weight loss treatment